Evidence map›Paper›PMID 36017364›Full record

ArticleFrontiers in cellular and infection microbiology2022

Assessment of IgG3 as a serological exposure marker for

Yanie Tayipto, Jason Rosado, Dionicia Gamboa, Michael T White, Benson Kiniboro, Julie Healer, D Herbert Opi, James G Beeson, Eizo Takashima, Takafumi Tsuboi and 4 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in cellular and infection microbiology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.8field-weighted citation impact, top 27% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 4 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 9 institutions in 5 countries.

Yanie TayiptoPopulation Health and Immunity Division, Walter and Eliza Hall Institute of Medical Research, Melbourne, VIC, Australia.
Jason RosadoUnité Malaria: Parasites et Hôtes, Département Parasites et Insectes Vecteurs, Institut Pasteur, Paris, France.
Dionicia GamboaLaboratorio International Centers of Excellence for Malaria Research (ICEMR)-Amazonia, Laboratorios de Investigación y Desarrollo, Facultad de Ciencias y Filosofía, Universidad Peruana Cayetano Heredia, Lima, Peru.
Michael T WhiteUnité Malaria: Parasites et Hôtes, Département Parasites et Insectes Vecteurs, Institut Pasteur, Paris, France.
Benson KiniboroVector Borne Disease Unit, Papua New Guinea Institute of Medical Research, Goroka, Papua New Guinea.
Julie HealerPopulation Health and Immunity Division, Walter and Eliza Hall Institute of Medical Research, Melbourne, VIC, Australia.
D Herbert OpiLife Sciences, Burnet Institute, Melbourne, VIC, Australia.
James G BeesonLife Sciences, Burnet Institute, Melbourne, VIC, Australia.
Eizo TakashimaProteo-Science Center, Ehime University, Matsuyama, Japan.
Takafumi TsuboiProteo-Science Center, Ehime University, Matsuyama, Japan.
Matthias HarbersCellFree Sciences Co., Ltd., Yokohama, Japan.
Leanne RobinsonPopulation Health and Immunity Division, Walter and Eliza Hall Institute of Medical Research, Melbourne, VIC, Australia.
Ivo MuellerPopulation Health and Immunity Division, Walter and Eliza Hall Institute of Medical Research, Melbourne, VIC, Australia.
Rhea J LongleyPopulation Health and Immunity Division, Walter and Eliza Hall Institute of Medical Research, Melbourne, VIC, Australia.
University of Melbourne · AUEhime University · JPInstitut Pasteur · FRBurnet Institute · AUCellFree Sciences (Japan) · JPMonash University · AUPapua New Guinea Institute of Medical Research · PGUniversidad Peruana Cayetano Heredia · PEWalter and Eliza Hall Institute of Medical Research · AU

Funding

Sugar-feeding behavior of the malaria vector Nyssorhynchus darlingi and development of effective attractive toxic sugar baits (ATSB) to increase intervention success in PeruU19AI089681 · NIAID · YALE UNIVERSITY · PI VINETZ, JOSEPH M. · 2010 to 2023
$20.1M
TransmissionU19AI089686 · NIAID · CASE WESTERN RESERVE UNIVERSITY · PI KAZURA, JAMES WALTER · 2010 to 2016
$9.9M
Understanding, tracking and eliminating malaria transmission in the Asia - Pacific RegionU19AI129392 · NIAID · WALTER AND ELIZA HALL INST MEDICAL RES · PI Ivo J Mueller · 2017 to 2026
$7.1M
NIAID NIH HHS U19 AI089681NIAID NIH HHS U19 AI089686NIAID NIH HHS U19 AI129392
6 · The paper itself

Abstract

A more sensitive surveillance tool is needed to identify

Indexed as

MalariaMalaria, FalciparumMalaria, VivaxAdolescentAdultAgedAged, 80 and overAntibodies, ProtozoanAsymptomatic InfectionsBiomarkersChildChild, PreschoolHumansImmunoglobulin GImmunoglobulin MMiddle AgedAntibodies, ProtozoanBiomarkersImmunoglobulin GImmunoglobulin MantibodyIgG3malariamalaria eliminationmultiplex assayPlasmodium vivaxsurveillance

Identifiers

PMID36017364
PMCPMC9395743
OpenAlexW4290730479

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.